Table I.
Baseline demographic and clinical characteristics.
| Variable | FOLFOX, n=87 (%) | EOX, n=26 (%) | t/χ2 | P-value |
|---|---|---|---|---|
| Age | 59.39±10.59 | 55.19±9.52 | 1.813 | 0.073 |
| Gender | ||||
| Male | 64 (73.6) | 19 (73.1) | 0.002 | 0.961 |
| Female | 23 (26.4) | 7 (26.9) | ||
| Tumour location | 0.908 | 0.341 | ||
| Upper body | 14 (16.1) | 2 (7.7) | ||
| Middle body | 21 (24.1) | 7 (26.9) | ||
| Lower body | 47 (54) | 14 (53.8) | ||
| Diffuse type | 5 (5.7) | 3 (11.5) | ||
| Tumour differentiation | 2.009 | 0.571 | ||
| Differentiated | 29 (33.3) | 8 (30.8) | ||
| Undifferentiated | 58 (66.7) | 18 (69.2) | ||
| Clinical T classification | 0.444 | 0.801 | ||
| T2 | 9 (10.3) | 2 (7.7) | ||
| T3 | 44 (50.6) | 15 (57.7) | ||
| T4 | 34 (39.1) | 9 (34.6) | ||
| Clinical N classification | 0.209 | 0.647 | ||
| N− | 31 (35.6) | 8 (30.8) | ||
| N+ | 56 (64.4) | 18 (69.2) | ||
| Tumour size, cm | ||||
| <6 | 53 (60.9) | 16 (61.5) | ||
| >6 | 34 (39.1) | 10 (38.5) | ||
| Chemotherapy cycles | 3.86±1.85 | 3.80±1.36 | 0.139 | 0.890 |